# EDGAR Filing Document

**Accession Number:** 0001760854
**File Stem:** 0001171843-25-006906
**Filing Date:** 2025-11
**Character Count:** 5613
**Document Hash:** 0a79773e52f92a66fecbcda8577af73a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-006906.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0001171843-25-006906

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251103

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nanobiotix S.A.
- **CENTRAL INDEX KEY:** 0001760854
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39777
- **FILM NUMBER:** 251444267

**BUSINESS ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012
- **BUSINESS PHONE:** 33140260470

**MAIL ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2025**

Commission File Number: **001-39777**

**Nanobiotix S.A.**

(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

On November 3, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[(c) Exhibit 99.1. Press release dated November 3, 2025](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Nanobiotix S.A.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: November 3, 2025 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Bart Van Rhijn&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Bart Van Rhijn |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**NANOBIOTIX to Participate in Investor Conferences the Week of November 10th**

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- <u>NANOBIOTIX</u> (Euronext: NANO - NASDAQ: NBTX - the "**Company**"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:

**UBS Global Healthcare Conference**

Date: Monday, November 10, 2025

Time: 5pm ET / 11pm CET

Location: Palm Beach Gardens, FL

Presenter: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

**Guggenheim's Annual Healthcare Innovation Conference** 

Date: Monday, November 10, 2025

Time: 4:30pm ET / 10:30pm CET

Location: Boston, MA

Presenter: Laurent Levy, Chief Executive Officer of Nanobiotix

Webcast link: Click here

**Stifel Healthcare Conference**

Date: Thursday, November 13, 2025

Time: 8am ET / 2pm CET

Location: New York, NY

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

The recorded fireside chats will be webcast live from the events page of the Investors section of the Company's website. Replay of the webcast will be available following the event.

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

**Contacts**

---

| | |
|:---|:---|
| *Nanobiotix* | *Nanobiotix* |
| **Communications Department**<br>*Brandon Owens*<br>*VP, Communications*<br>+1 (617) 852-4835<br>contact@nanobiotix.com | **Investor Relations Department**<br>*Joanne Choi*<br>*VP, Investor Relations (US)*<br>+1 (713) 609-3150<br>*Ricky Bhajun*<br>*Director, Investor Relations (EU)*<br>+33 (0) 79 97 29 99<br>investors@nanobiotix.com |
| *Media Relations* | *Media Relations* |
| <br>France – **HARDY**<br>Caroline Hardy<br>+33 06 70 33 49 50<br><u>carolinehardy@outlook.fr</u> | <br>Global – **uncapped**<br>Becky Lauer <br>+1 (646) 286-0057<br><u>uncappednanobiotix@uncappedcommunications.com</u> |

---

**Attachments**

* 2025-11-03 -- NBTX -- Presenting @ November Conferences -- FINAL (https://ml.globenewswire.com/Resource/Download/c63c2690-87e0-4d9e-ad5a-75006124a1d4)